XELLIA PHARMACEUTICALS ApS
CVR number: 61094628
Dalslandsgade 11, 2300 København S
tel: 32645500
Income statement (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 2 346.00 | 2 043.00 | 1 622.00 | 2 245.30 | 1 986.82 |
| Costs of manufacturing | -2 013.04 | -2 627.03 | |||
| Gross profit | 2 346.00 | 2 043.00 | 1 622.00 | 232.27 | - 640.21 |
| Costs of management | - 267.90 | - 247.67 | |||
| Costs of distribution | - 112.01 | -80.23 | |||
| Other operating expenses | - 237.81 | - 218.93 | |||
| EBIT | 2 346.00 | 2 043.00 | 1 622.00 | - 385.46 | -1 187.04 |
| Other financial income | 16.35 | 54.81 | |||
| Other financial expenses | - 133.80 | -69.37 | |||
| Reduction non-current investment assets | 0.24 | ||||
| Net income from associates (fin.) | 14.78 | -1 440.14 | |||
| Pre-tax profit | 391.00 | - 116.00 | - 503.00 | - 488.37 | -2 641.74 |
| Income taxes | 116.88 | 256.84 | |||
| Net earnings | 391.00 | - 116.00 | - 503.00 | - 371.49 | -2 384.90 |
Assets (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Development expenditure | 48.21 | 36.23 | |||
| Intangible rights | 85.27 | 76.91 | |||
| Goodwill | 0.41 | ||||
| Intangible assets total | 133.90 | 113.14 | |||
| Land and waters | 54.28 | 59.21 | |||
| Buildings | 227.04 | 232.34 | |||
| Machinery and equipment | 25.24 | 27.84 | |||
| Advance payments and construction in progress | 290.52 | 144.47 | |||
| Tangible assets total | 597.08 | 463.86 | |||
| Holdings in group member companies | 1 658.38 | 205.32 | |||
| Other receivables | 2 652.00 | 4 091.00 | 3 734.00 | ||
| Investments total | 2 652.00 | 4 091.00 | 3 734.00 | 1 658.38 | 205.32 |
| Long term receivables total | |||||
| Semifinished products | 166.70 | 215.22 | |||
| Raw materials and consumables | 50.85 | 74.75 | |||
| Finished products/goods | 281.71 | 283.06 | |||
| Inventories total | 499.27 | 573.03 | |||
| Current trade debtors | 275.88 | 199.65 | |||
| Current amounts owed by group member comp. | 158.34 | 256.99 | |||
| Prepayments and accrued income | 33.43 | 29.90 | |||
| Current other receivables | 103.66 | 124.59 | |||
| Current deferred tax assets | 138.25 | ||||
| Short term receivables total | 571.31 | 749.39 | |||
| Cash and bank deposits | 0.32 | 0.25 | |||
| Cash and cash equivalents | 0.32 | 0.25 | |||
| Balance sheet total (assets) | 2 652.00 | 4 091.00 | 3 734.00 | 3 460.25 | 2 105.00 |
Equity and liabilities (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 1 391.00 | 2 621.00 | 2 083.00 | 201.00 | 201.00 |
| Other reserves | 6.35 | 4.87 | |||
| Other restricted equity | -8.20 | 28.25 | |||
| Retained earnings | - 391.00 | 116.00 | 503.00 | 1 923.00 | 1 553.00 |
| Profit of the financial year | 391.00 | - 116.00 | - 503.00 | - 371.49 | -2 384.90 |
| Shareholders equity total | 1 391.00 | 2 621.00 | 2 083.00 | 1 750.67 | - 597.77 |
| Provisions | 54.56 | 121.25 | |||
| Non-current loans from credit institutions | 170.06 | 150.51 | |||
| Non-current leasing loans | 0.59 | 1.31 | |||
| Non-current advances received | 41.17 | 42.18 | |||
| Non-current owed to group member | 324.20 | 313.63 | |||
| Non-current owed to participating | 9.96 | 14.24 | |||
| Non-current deferred tax liabilities | 13.60 | 16.39 | |||
| Non-current liabilities total | 559.59 | 538.26 | |||
| Current loans from credit institutions | 22.61 | 22.21 | |||
| Current trade creditors | 169.31 | 120.86 | |||
| Current owed to participating | 124.16 | ||||
| Current owed to group member | 497.63 | 1 741.39 | |||
| Short-term deferred tax liabilities | 114.01 | ||||
| Other non-interest bearing current liabilities | 167.72 | 158.81 | |||
| Current liabilities total | 1 095.43 | 2 043.27 | |||
| Balance sheet total (liabilities) | 1 391.00 | 2 621.00 | 2 083.00 | 3 460.25 | 2 105.00 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.